Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Grants & Contracts
Research output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
23-HN-38-BG(BGB-HNSCC-201):A Phase 2, Randomized, Open-label, multi-arm Study of Tislelizumab in Combination with Investigational Agents as First Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Arnold, Susanne
(PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Active
Effective start/end date
10/26/23
→
10/26/25
Funding
BeiGene USA Incorporated:
$2.00
View all
View less